173 related articles for article (PubMed ID: 21933889)
1. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.
Sonpavde G; Thompson TC; Jain RK; Ayala GE; Kurosaka S; Edamura K; Tabata K; Ren C; Goltsov AA; Mims MP; Hayes TG; Ittmann MM; Wheeler TM; Gee A; Miles BJ; Kadmon D
Clin Cancer Res; 2011 Nov; 17(22):7174-82. PubMed ID: 21933889
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy.
Kumon H; Ariyoshi Y; Sasaki K; Sadahira T; Araki M; Ebara S; Yanai H; Watanabe M; Nasu Y
Cancer Gene Ther; 2016 Nov; 23(11):400-409. PubMed ID: 27767086
[TBL] [Abstract][Full Text] [Related]
3. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer.
Rojas-Martínez A; Manzanera AG; Sukin SW; Esteban-María J; González-Guerrero JF; Gomez-Guerra L; Garza-Guajardo R; Flores-Gutiérrez JP; Elizondo Riojas G; Delgado-Enciso I; Ortiz-López R; Aguilar LK; Butler EB; Barrera-Saldaña HA; Aguilar-Cordova E
Cancer Gene Ther; 2013 Nov; 20(11):642-9. PubMed ID: 24052127
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of Neoadjuvant Ad-REIC Gene Therapy in Patients with High-Risk Localized Prostate Cancer Undergoing Radical Prostatectomy.
Kumon H; Sasaki K; Ariyoshi Y; Sadahira T; Araki M; Ebara S; Yanai H; Watanabe M; Nasu Y
Clin Transl Sci; 2015 Dec; 8(6):837-40. PubMed ID: 26621187
[TBL] [Abstract][Full Text] [Related]
5. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer.
Pisters LL; Pettaway CA; Troncoso P; McDonnell TJ; Stephens LC; Wood CG; Do KA; Brisbay SM; Wang X; Hossan EA; Evans RB; Soto C; Jacobson MG; Parker K; Merritt JA; Steiner MS; Logothetis CJ
Clin Cancer Res; 2004 Apr; 10(8):2587-93. PubMed ID: 15102659
[TBL] [Abstract][Full Text] [Related]
6. Glioma pathogenesis-related protein 1: tumor-suppressor activities and therapeutic potential.
Thompson TC
Yonsei Med J; 2010 Jul; 51(4):479-83. PubMed ID: 20499410
[TBL] [Abstract][Full Text] [Related]
7. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
[TBL] [Abstract][Full Text] [Related]
9. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models.
Fujita T; Satoh T; Timme TL; Hirayama T; Zhu JX; Kusaka N; Naruishi K; Yang G; Goltsov A; Wang J; Vlachaki MT; Teh BS; Brian Butler E; Thompson TC
Urol Oncol; 2014 Feb; 32(2):92-100. PubMed ID: 23433894
[TBL] [Abstract][Full Text] [Related]
10. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Blank K; Broderick GA; Tomaszewski JE; Renshaw AA; Kaplan I; Beard CJ; Wein A
JAMA; 1998 Sep; 280(11):969-74. PubMed ID: 9749478
[TBL] [Abstract][Full Text] [Related]
11. Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model.
Tabata K; Kurosaka S; Watanabe M; Edamura K; Satoh T; Yang G; Abdelfattah E; Wang J; Goltsov A; Floryk D; Thompson TC
Gene Ther; 2011 Oct; 18(10):969-78. PubMed ID: 21512508
[TBL] [Abstract][Full Text] [Related]
12. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
13. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
[TBL] [Abstract][Full Text] [Related]
14. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
15. Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups.
Stamey TA; Sözen TS; Yemoto CM; McNeal JE
J Urol; 1998 Jun; 159(6):2009-12. PubMed ID: 9598508
[TBL] [Abstract][Full Text] [Related]
16. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.
Nosov A; Reva S; Petrov S; Mamijev E; Novikov R; Veliev E; Imkamp F; Tolkach Y; Moiseenko V
Prostate; 2016 Nov; 76(15):1345-52. PubMed ID: 26864707
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
[TBL] [Abstract][Full Text] [Related]
19. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
Keyser D; Kupelian PA; Zippe CD; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):723-9. PubMed ID: 9240638
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer.
Sella A; Zisman A; Kovel S; Yarom N; Leibovici D; Lindner A
Urology; 2008 Feb; 71(2):323-7. PubMed ID: 18308112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
